Mylan’s generic laxative receives FDA approval
PITTSBURGH The Food and Drug Administration has approved a generic laxative made by Mylan, the company announced Wednesday.
The FDA approved Mylan’s polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution with flavor packs.
The drug is a generic version Braintree Labs’ NuLytely, which had sales of around $31 million in 2009, accordimg to IMS Health. Mylan said its version of the drug was available for immediate shipment.
Kevin Tripp joins Asteres’ board
SAN DIEGO A provider of automated pharmacy and wellness kiosks has named a retail veteran to its board of directors.
Asteres, maker of ScriptCenter, appointed Kevin Tripp, a former EVP and Midwest division president at Supervalu, to its board. Tripp joined Supervalu the 2006 acquisition of Albertsons, where he served as EVP drug operations and drug store division president, as well as a member of the corporation’s executive council that directed food and drug operations in 37 states. Tripp’s additional prior affiliations included National Association of Chain Drug Stores, as an executive board member, executive committee member and charitable foundation board member. He also served as a board member for the University of Southern Nevada’s College of Pharmacy.
“We are excited to have Kevin join our board,” said Mark de Bruin, Asteres CEO. “Kevin’s wealth of retail operations expertise will be of great value to Asteres as ScriptCenter expands in pharmacy and into the front of the store for health and wellness products.”
NanoGuardian announces partnership with security firm
SKOKIE, Ill. Security firm Altegrity Risk International has signed on as security partner for a company developing technology to keep diverted and counterfeited drugs out of the supply chain.
NanoGuardian announced the partnership with ARI Tuesday, which it said will help deliver its Closed-Loop Protection program to manufacturers. Closed-Loop Protection works with NanoEncryption, in which a special code is imprinted onto the surface of a drug and uses a statistical modeling and randomized pharmacy auditing system to identify counterfeit and diverted drugs on pharmacy shelves.
“NanoGuardian is committed to forging relationships with best-of-class partners in our effort to protect patients and brands,” NanoGuardian EVP Dean Hart said. “We are very excited to announce another such partnership with ARI, a global leader in corporate security with significant experience in the pharmaceutical space.”